@article{oai:niigata-u.repo.nii.ac.jp:00012679,
 author = {坂爪, 重明},
 issue = {2},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Feb},
 note = {Genetic polymorphisms at -1293, -1053, -352, -333, -71, 1132 and 7632 of CYP2E1 and nonnull or null type of GSTM1 were examined in 101 Japanese patients given 0.3-1.35g of acetaminophen(APAP) orally in Niigata University Medical Hospital and 125 healthy Japanese volunteers using PCR-based analysis. In the CYP2E1 and GSTM1 genotype frequencies there was no dif-ference between the patients and the volunteers(p>0.1). The sites of -71 and 1132 were monomorphic in 226 DNA samples. For Pst I(-1293)/Rsa I(-1053) and Dra I(7632) sites of the CYP2E1 gene, haplotype frequencies were also estimated by a method with Arlequin Software. The outcome of the calculation showed that all variant alleles (CYP2E1^*5), recognized by the Pst I, but not by the Rsa I, carried variant allele A of Dra I sites. At the Dra I sites, 65% of all A alleles carried CYP2E1^*5 allele, which could possibly affect its transcription. Seven of the 101 patients were caused drug-induced liver damage by the APAP ingestion. Of the seven patients, one had developed serious liver damage. There was no difference between hepatotoxicity (+) -patients(n=7) and hepatotoxicity (-) -patients(n=94) either in the CYP2E1 genotype frequencies(p>0.06) or in GSTM1(p=0.84). However, the sample number of the hepatotoxicity (+) -patients is too small to evaluate the association between genotypic differences and liver damage by acetaminophen. Of interest was the observation that the genotype CYP2El^*5/^*5was not found in the hepatotoxicity(+) -patients, but was found in three of the hepatotoxicity(-) -patients. In this study, no association was found between CYP2E1 and GSTM1 polymorphisms examined and APAP-induced liver damage.},
 pages = {95--105},
 title = {アセトアミノフェンによる肝障害と日本人におけるCYP2E1,GSTM1の遺伝子多型との関連について},
 volume = {119},
 year = {2005}
}